This activity serves as an educational tool for pharmacists seeking Board Certified Psychiatric Pharmacist (BCPP) Recertification credit and other pharmacists and health care providers seeking advanced education in patient management, disease state management, information management, and health policy and practice management in the field of psychiatric pharmacy.
Content
The AAPP Substance Use Disorder (SUD) Summit content is intended to improve your ability to care for patients with substance use disorder(s) and mental illness. The SUD Summit offers 10 hours of ACPE- and BCPP- approved programming focused on the complicated relationships between substance use disorders and mental illness. The goal of the Summit is for participants to leave with knowledge and tools to apply in their practice setting as they provide care to those living with substance use and mental health disorders.
The curriculum includes:
Online access to the recorded speakers' audio presentations synchronized with their slide presentations (presented live during the Virtual SUD Summit, October 6-7, 2022).
For pharmacists, 10 hours of ACPE credit and 10 hours of BCPP Recertification credit achieved by successfully completing the online CPNP recertification examination.
Access to the CPNP testing center with exam submission due on or before July 6, 2023.
The AAPP Summit 2022 is an application-based continuing pharmacy education (CPE) activity designed to improve competency of partcipants. An application-based CPE activity requires that participants apply the information learned. In an application-based CPE activity, the learning objectives are written at a higher level in order to assess the learners’ ability to use the information that is learned at the current level of practice by Board Certified Psychiatric Pharmacists. The examination for this product often features case studies requiring that the participant apply the principles learned through the readings.
Course Requirements
To satisfactorily complete the Summit and receive 10 hours of BCPP Recertification and ACPE credit, candidates must meet the following requirements:
Abide by a confidentiality and honesty statement requiring individual completion of the Recertification education.
Complete an online assessment on or before the deadline of July 6, 2023.
Meet the minimum passing score to be determined by a panel of experts within four (4) weeks following the exam deadline.
Completion of an activity evaluation form.
Partial credit is not available for individual topics within the programming; it is either all 10 hours of credit or none.
You will proceed through the following steps to satisfactorily complete this course:
Sign in (or create a FREE account).
Register for this course.
Complete the pre-test before starting the activity.
Review the full content of the activity and reflect upon its teachings.
Complete the post-test at the end of the activity no later than the closing activity date.
Complete the evaluation at the end of the activity.
Wait for the official review of exam questions within 4 weeks following the closing date.
Receive a passing grade (70%).
Provide the necessary details in your profile to ensure correct reporting by AAPP to CPE Monitor.
Credit is awarded in the calendar year the assessment is completed. AAPP reports continuing credit for ACPE (CPE Monitor) and BCPP Recertification (BPS) within days of successful exam completion.
AAPP has invested in supporting the most popular web browsers and leveraging software that our members use daily. Beyond PDF downloads, the rest of the system is built on HTML5, a technology that most up-to-date browsers will support. To access AAPP course materials online, you will need:
A modern web browser with JavaScript and cookies enabled: Chrome is strongly recommended,
or the latest version of Firefox or Safari.
A PDF reader: Chrome built-in, Firefox built-in, Acrobat
or FoxIt
An adequate device and Internet connection:
Processor: Dual-core 2Ghz or higher (Intel i3/i5/i7 or AMD equivalent);
Memory: 4 GB;
Storage: 5 GB available;
Internet speed: 4.0 Mbps (up/down)
AAPP web sites no longer fully support Microsoft Internet Explorer or Windows 8.1 and older. We cannot guarantee that the site will function perfectly on every device and configuration, but using the latest version of the software above will greatly improve your experience.
Faculty Information and Disclosures
Frederick S. Barrett, PhD Jacqueline Byrd, PharmD, BCPS, AAHIVP Phillip Coffin, MD, MIA, VACP, FIDCA Michelle Colvard, PharmD, BCPP David Dadiomov, PharmD, BCPP Kari Franson, PharmD, PhD, BCPP Danielle Stutzman, PharmD, BCPP Kristina Ward, PharmD, BCPS, BCPP
Frederick S. Barrett, PhD
Associate Professor of Psychiatry and Behavioral Sciences, Johns Hopkins School of Medicine, Department of Psychological & Brain Sciences, Krieger School of Arts & Sciences, Johns Hopkins University; Director of Neurophysiological Mechanism and Biomarker Assessment, Center for Psychedelic and Consciousness Research
Frederick Barrett is a cognitive neuroscientist with training in behavioral pharmacology. Dr. Barrett has been conducting psychedelic research at Johns Hopkins University since 2013, and his research in heathy participants and in patients with mood and substance use disorders focuses on the psychological and neurological mechanisms underlying the enduring therapeutic and other effects of psychedelic drugs. In 2017, he received an NIH “R03” grant as Principal Investigator to investigate biological mechanisms of psilocybin effects, the first federally funded research since the 1970s administering a classic psychedelic to people with psychedelic effects as the primary focus. He developed the first comprehensive questionnaire to measure subjective aspects of challenging experiences encountered with psilocybin. He also published the first studies in humans characterizing the enduring effects of psilocybin on the brain (up to a month after psilocybin administration), the effects of psilocybin on a brain structure called the claustrum (which has been proposed to variously mediate consciousness and cognition), the effects of LSD on the brain's response to music, and the effects of the atypical hallucinogen salvinorin A on human brain network function. He is currently leading clinical trials to investigate the use of psilocybin to treat patients with major depressive disorder and co-occurring alcohol use disorder, and he is leading a number of ongoing studies aimed at better understanding the psychological, biological, and neural mechanisms underlying therapeutic efficacy of psychedelic drugs.
No Relevant Financial Relationships to Disclose
Jacqueline Byrd, PharmD, BCPS, AAHIVP
Clinical Pharmacist Practitioner
Orlando VA Healthcare System
Orlando, FL
Dr. Jacqueline Byrd graduated from the University of Florida College of Pharmacy in Gainesville, FL in 2013. She completed her PGY-1 Pharmacy Residency at the North Florida/South Georgia Veterans Health System in Gainesville in June 2014. Upon completion of residency, Dr. Byrd transferred to the Orlando VA where she worked as an outpatient pharmacist at the Lake Baldwin Outpatient Clinic. In February 2015, she joined the Infectious Diseases Team at the Orlando VA where she currently serves as an HCV/HIV/ID Clinical Pharmacy Specialist in the outpatient clinic. She sees patients for pharmacotherapy management related to HIV and HIV PrEP, viral hepatitis, and other public health related infectious diseases.
She has been instrumental in the development and implementation of the Syringe Service Program (SSP) and continues to work with members of the ID Team to expand the program at the Orlando VA while also guiding other programs’ efforts in creating an SSP.
In 2018, she became the program director of the Pharmacy PGY-1 Residency Program after serving as a preceptor since 2015. She is an active member of the American Society of Health-System Pharmacists (ASHP) and the American Academy of HIV Medicine as a credentialed HIV pharmacist.
No Relevant Financial Relationships to Disclose
Phillip Coffin, MD, MIA, VACP, FIDCA
Director of Substance Use Research
San Francisco Department of Public Health
Division of HIV, ID & Global Medicine, University of California, San Francisco
San Francisco, CA
Phillip Coffin MD, MIA is a board-certified and practicing internist, infectious disease specialist, and addiction medicine specialist. He attended or trained at Brown University, Columbia University, the University of California San Francisco, and the University of Washington. He directs the Center on Substance Use and Health at the San Francisco Department of Public Health, including clinical trials assessing medications for multiple substance use disorders and interventions for opioid safety, overdose prevention, HIV prevention, and Hepatitis C treatment.​ Dr. Phillip Coffin also conducts several studies into the impacts of changing opioid prescribing practices on vulnerable populations, substance use epidemiology, and initiatives addressing substance use and opioid safety in clinical care.
No Relevant Financial Relationships to Disclose
Michelle Colvard, PharmD, BCPP
Clinical Pharmacist Practitioner, Substance Use Disorders
Nashville VA Medical Center
Nashville, TN
Dr. Colvard received her Doctor of Pharmacy degree from Samford University in 2011 in her hometown of Birmingham, AL. She completed PGY1 pharmacy residency at VA Tennessee Valley Healthcare System (TVHS) and PGY2 psychiatric pharmacy residency at the Medical University of South Carolina.
Dr. Colvard’s passion for treating patients with substance use disorders began when working to optimize management of alcohol and opioid withdrawal in her previous practice as an inpatient psychiatric pharmacist. She now practices as an outpatient Clinical Pharmacist Practitioner for Substance Use Disorders where she provides substance use disorder pharmacotherapy, ambulatory detoxification, and overdose prevention services. She also supports inpatient addiction consult and transitions of care services at her practice site to ensure SUD pharmacotherapy continuity across care settings.
No Relevant Financial Relationships to Disclose
David Dadiomov, PharmD, BCPP
Assistant Professor
University of Southern California School of Pharmacy
Los Angeles, CA
David Dadiomov, PharmD, BCPP, is a clinical assistant professor of pharmacy practice at the University of Southern California (USC). He received his PharmD from the University of Michigan College of Pharmacy. He completed his PGY1 Pharmacy Residency at Michigan Medicine, and his PGY2 Psychiatric Pharmacy Residency at University of California, San Diego, Health. He holds board certification in psychiatric pharmacy.
He is a credentialed clinical pharmacist within the LA County Department of Health Services where he provides direct patient care for individuals with mental illness, substance use disorders, experiencing homelessness, or incarcerated. He also co-manages clinical pharmacy programs within the county hospitals focused on transitions of care services. He serves as the Director for the PGY2 Psychiatric Pharmacy Residency Program at USC.
No Relevant Financial Relationships to Disclose
Kari Franson, PharmD, PhD, BCPP
Associate Dean of Academic & Student Affairs
University of Southern California School of Pharmacy
Los Angeles, CA
Kari L. Franson, PharmD, PhD, BCPP is Professor of Clinical Pharmacy and Associate Dean for Academic and Student Affairs at the University of Southern California School of Pharmacy. She received her doctor of pharmacy from the University of California, San Francisco, trained at the University of Illinois, Chicago Hospital and Clinics as a resident in adult internal medicine and a fellow in clinical research/drug development, and received her PhD in medical education from Leiden University, the Netherlands.
Dr. Franson is an educator with more than 25 years of experience. She is an international leader in interprofessional practice, education and advocacy and workforce development to address health disparities in both the U.S. and abroad. Dr. Franson has experience in campus and distance-based curriculum development and assessment, technology-enhanced assessment/learning, experiential education, and continuing professional education and development.
Dr. Franson has trained as a U.S. Board-Certified Psychiatric Pharmacist and Dutch-Certified Clinical Pharmacologist. She worked with geriatric psychiatric patients for 10 years and has performed a variety of clinical studies spanning those in early-phase clinical pharmacology to post-marketing clinical efficacy studies. She is interested in cannabinoid clinical pharmacologic effects and cannabis user safety. She has guided national and international professional, legislative, media and commercial groups on the wise study and use of cannabis.
Danielle Stutzman, PharmD, BCPP
Assistant Adjoint Professor, Psychiatry-Child-CHC,
School of Medicine, University of Colorado
Clinical Pharmacist-Psychiatry
Children’s Hospital Colorado
Aurora, CO
Danielle Stutzman, PharmD, BCPP, is a Clinical Assistant Professor at the University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences and serves as a Psychiatric Pharmacist at the Pediatric Mental Health Institute at Children’s Hospital Colorado. Dr. Stutzman serves as an integral member of inpatient, partial hospitalization, and outpatient child and adolescent psychiatry treatment teams to ensure optimal use of psychotropic medications among youth and leads medication education groups for adolescents and caregivers. She provides formal lectures for child and adolescent psychiatry fellows, developmental pediatrics fellows, pharmacy students, and serves as a training preceptor for pharmacy students and residents.
No Relevant Financial Relationships to Disclose
Kristina Ward, PharmD, BCPS, BCPP
Clinical Pharmacy Specialist
VA Northern California Health Care System
Martinez, CA
Dr. Kristina Ward graduated from the University of Wisconsin School of Pharmacy and completed her PGY-1 residency at the Clement J Zablocki VA Medical Center in Milwaukee, Wisconsin. Following her residency, she worked as a Clinical Pharmacy Specialist in Primary Care at the Zablocki VA before moving to Northern California and stepping into the role of Clinical Pharmacist Practitioner in General Mental Health at the VA Northern California Healthcare System Martinez Clinic in 2009.
Dr. Ward works as a mid-level provider in the Outpatient Behavioral Health Clinic providing individual and group medication management services. She is involved in teaching through precepting both PGY-1 and PGY-2 residents in mental health and Pharmacy Benefits rotations. Dr. Ward has also been a regular guest lecturer for the Physician Assistant Program at Samuel Merritt University in Oakland, California and served as a Clinical Instructor for the University of Wisconsin School of Pharmacy.
Dr. Ward has been involved in quality improvement projects focused on reducing benzodiazepine prescribing and co-authored AAPP’s Pharmacist Toolkit on benzodiazepine tapering.
No Relevant Financial Relationships to Disclose
Learning Objectives
Topic
A New Wave of Cannabis Concerns: The Potential Sequelae of Chronic Cannabis Use
ACPE #:0284-0000-22-070-L01-P (Application) Speaker: Kari Franson, PharmD, PhD, BCPP
Learning Objectives:
Illustrate the risk of marijuana use, change in potency, and routes of administration on developing of Cannabis use disorder and other psychiatric disorders.
Evaluate the evidence for managing Cannabis use disorder, Cannabis withdrawal, and cannabinoid hyperemesis syndrome.
Construct management plans for cannabis use disorder, cannabinoid hyperemesis syndrome, and Cannabis withdrawal.
Why Do I Need to Taper? Challenges and Evidence Behind Benzodiazepine Discontinuation
ACPE #: 0284-0000-22-071-L01-P (Application) Speaker: Kristina Ward, PharmD, BCPS, BCPP
Learning Objectives:
Identify adverse events secondary to chronic benzodiazepine use.
Recommend evidence-based non-pharmacologic and pharmacologic strategies for addressing barriers to successful tapering of benzodiazepines.
Design a benzodiazepine tapering protocol based on patient-specific characteristics that minimizes withdrawal symptoms.
Pre-exposure Prophylaxis (PrEP) for HIV in Persons Who Inject Drugs
ACPE #: 0284-0000-22-072-L04-P (Application) Speaker: Jacqueline Byrd, PharmD, BCPS, AAHIVP
Learning Objectives:
Assess a patient for risk of HIV acquisition through injection practices.
Evaluate evidence supporting PrEP prescribing in persons who inject drugs (PWID).
Implement guideline-driven PrEP-prescribing principles about treatment initiation and appropriate monitoring principles in PWID.
The Revolving Door: Improving Transitions of Care for Incarcerated Persons with Opioid Use Disorder ACPE #: 0284-0000-22-073-L08-P (Application) Speaker: David Dadiomov, PharmD, BCPP
Learning Objectives:
Analyze barriers to provide medications for opioid use disorder (MOUD) and consequences of the lack of access to care at time of release from incarceration.
Evaluate the literature regarding role of subcutaneous buprenorphine and long-acting naltrexone before transition back into the community.
Construct a pharmacotherapy plan for MOUD at time of transition from incarceration back into the community.
Therapeutic Uses of Psychedelics ACPE #: 0284-0000-22-074-L01-P (Application) Speaker: Frederick S. Barrett, PhD
Learning Objectives:
Assess patients who may benefit from psychedelic compounds to treat their psychiatric or substance use disorder.
Implement best practices regarding treatment initiation and appropriate monitoring in persons with psychiatric or substance use disorders.
Evaluate evidence supporting psychedelic therapy in persons with psychiatric and substance use disorders.
A Case-Based Approach to Managing the Complexities of Co-Occurring OUD and AUD ACPE #: 0284-0000-22-075-L08-P (Application) Speaker: Michelle Colvard, RPH, PharmD, BCPP
Learning Objectives:
Describe the clinical considerations for co-occurring opioid and alcohol use disorders.
Evaluate the evidence for treatment of co-occurring opioid and alcohol use disorders.
Develop a treatment plan for a patient scenario with co-occurring opioid and alcohol use disorders.
A Stimulating Discussion on Stimulant Use Disorder ACPE #: 0284-0000-22-076-L01-P (Application) Speaker: Phillip Coffin, MD, MIA, FACP, FIDSA
Learning Objectives:
Explain the prevalence and consequences of stimulant misuse and stimulant use disorders in the United States.
Evaluate the evidence supporting pharmacotherapies for stimulant use disorders.
Provide patient education and harm reduction strategies to prevent long-term consequences of stimulant use disorder.
Recognizing and Managing Co-occurring Substance Use and Eating Disorders ACPE #: 0284-0000-22-077-L01-P (Application) Speaker: Danielle Stutzman, PharmD, BCPP
Learning Objectives:
Illustrate the prevalence and overlapping risk factors for co-occurring substance use disorders and eating disorders.
Categorize the risks of substances most frequently misused in persons with eating disorder.
Choose treatment strategies (non-pharmacologic and pharmacotherapy) for a patient with co-occurring eating disorder and substance use disorder.
The College of Psychiatric and Neurologic Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Pharmacists can obtain 10 hours of ACPE credit and 10 hours of BCPP Recertification credit by successfully completing the online examination.
The College of Psychiatric and Neurologic Pharmacists is approved as a Professional Development Provider for the Board Certified Psychiatric Pharmacist (BCPP) specialty by the Board of Pharmacy Specialties (BPS). (Applicable to programs where individual sessions are listed on separate course pages). This course is part of a 10 hour BCPP recertification product earned after successful completion of the associated BCPP recertification examination for the full product.
AAPP owns the copyright, is licensed or has received permissions for use of, or is otherwise permitted to use copyrighted materials within any CPE activity. Authors and speakers are required to obtain necessary copyright permissions for content in CPE activities. AAPP complies with copyright laws and regulations.
This activity may include discussions of products or devices that are not currently approved for use by the Food and Drug Administration (FDA), or are currently investigational.
In accordance with the Food and Drug Administration (FDA), it is disclosed that there is the potential for discussions concerning off-label uses of a commercial product/devices during this educational activity.
Any person who may contribute to the content of this continuing education activity must disclose significant relationships (and any known relationships of their spouse/partner) with commercial companies whose products or services are discussed in this activity. Significant relationships include receiving from a commercial company research grants, consultant fees, travel, other benefits, or having a self-managed equity interest in a company.
Disclosure of a relationship is not intended to suggest or condone any bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.
It is the policy of AAPP to ensure independence, balance, objectivity, scientific rigor, and integrity in continuing education activities. Those involved in the development of this continuing education activity have made all reasonable efforts to ensure that information contained herein is accurate in accordance with the latest available scientific knowledge at the time of accreditation of this continuing education activity. Information regarding drugs (e.g., their administration, dosages, contraindications, adverse reactions, interactions, special warnings, and precautions) and drug delivery systems is subject to change, however, and the reader is advised to check the manufacturer’s package insert for information concerning recommended dosage and potential problems or cautions prior to dispensing or administering the drug or using the drug delivery systems.
Fair balance is achieved through ongoing and thorough review of all materials produced by faculty, and all educational and advertising materials produced by supporting organizations, prior to educational offerings. Approval of credit for this continuing education activity does not imply endorsement by AAPP for any product or manufacturer identified.
AAPP websites use cookies to personalize and enhance your experience.
By continuing to use the site, you agree to this collection.
Learn more.
System Update:
We are undergoing major upgrades right now, and we appreciate your patience.
If you need help, please use the support chat or email info@aapp.org.
Learn more.
The College of Psychiatric and Neurologic Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Pharmacists can obtain 10 hours of ACPE credit and 10 hours of BCPP Recertification credit by successfully completing the online examination.